We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
170 hedge funds and large institutions have $319M invested in ANI Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 64 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
40% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $1.11M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 173 → 170 (-3)
3.7% less ownership
Funds ownership: 63.45% → 59.76% (-3.7%)
19% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 64
25% less capital invested
Capital invested by funds: $424M → $319M (-$105M)
Holders
170
Holders Change
-3
Holders Change %
-1.73%
% of All Funds
3.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
52
Reduced
64
Closed
22
Calls
$1.55M
Puts
$1.11M
Net Calls
+$440K
Net Calls Change
-$198K
Top Buyers
Top Sellers
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$12.1M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$10.8M |
| 3 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
-$4.14M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.13M |
| 5 |
Goldman Sachs
New York
|
-$2.78M |
